Table 1 Demographic and clinical characteristics of study participants

Age

70.3 ± 6.3

71.3 ± 6.5

69.5 ± 9.0

0.606

Education

10.4 ± 5.0

9.8 ± 5.8

9.1 ± 4.6

0.249

Female, n (%)

46 (49.5)

13 (56.5)

36 (52.2)

0.820

APOE ε4 carrier,^a n (%)

16 (17.2)

17 (77.3)

42 (60.9)

< 0.001

MMSE

26.6 ± 2.6

25.0 ± 4.5

22.4 ± 5.4^*†

< 0.001

GDS

10.6 ± 6.9

9.6 ± 6.6

10.6 ± 6.5

0.822

CN/MCI/AD, n

41/52/0

6/12/5

3/31/35

< 0.001

CDR^a 0, n (%)

41 (44.1)

7 (30.4)

3 (4.3)

< 0.001

 0.5, n (%)

52 (55.9)

15 (65.2)

43 (62.3)

 1, n (%)

0 (0.0)

1 (4.3)

22 (31.9)

 Aβ_1–42

516.8 ± 98.4

224.5 ± 104.4^*

235.2 ± 88.9^*

< 0.001

 p-Tau₁₈₁

29.3 ± 5.5

31.2 ± 5.8

60.2 ± 13.2^*†

< 0.001

 t-Tau

49.6 ± 13.1

48.6 ± 16.0

108.7 ± 40.2^*†

< 0.001

 L. HC

3951 ± 50

3675 ± 105

3215 ± 61^*†

< 0.001

 R. HC

4202 ± 57

4002 ± 118

3498 ± 69^*†

< 0.001

 L. EC

3.28 ± 0.04

3.28 ± 0.08

2.79 ± 0.05^*†

< 0.001

 R. EC

3.52 ± 0.04

3.52 ± 0.09

3.11 ± 0.05^*†

< 0.001